Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2014; 20(20): 5973-5986
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.5973
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.5973
MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: Current status and future prospects
Yi Lin Jane Tan, Wei Ning Chen, School of Chemical and Biomedical Engineering, College of Engineering, Nanyang Technological University, Singapore 637459, Singapore
Author contributions: Tan YLJ and Chen WN contributed to the conception and design, acquisition, analysis and interpretation of data; Tan YLJ drafted the article and revised it critically for important intellectual content; Chen WN gave the final approval of the version to be published.
Correspondence to: Wei Ning Chen, Professor, School of Chemical and Biomedical Engineering, College of Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore 637459, Singapore. wnchen@ntu.edu.sg
Telephone: +65-6-3162870 Fax: +65-6-2259865
Received: October 28, 2013
Revised: January 13, 2014
Accepted: April 8, 2014
Published online: May 28, 2014
Processing time: 211 Days and 20.5 Hours
Revised: January 13, 2014
Accepted: April 8, 2014
Published online: May 28, 2014
Processing time: 211 Days and 20.5 Hours
Core Tip
Core tip: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is a complex cancer of the liver stemming from the long term infection of the virus. MiRNAs are found to be involved in a multitude of events, ranging from the diagnosis, pathogenesis as well as possibly in the treatment of this cancer. This review explores the current knowledge in understanding the role of miRNAs in HBV-related HCC, and how it is able to regulate, or be regulated, such that important cellular processes may be affected.